On November 11, 2026 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") will participate in the upcoming UBS Global Biopharma Conference in London (UK).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Christian Behrenbruch, Managing Director and Group CEO, and Mr. Richard Valeix, CEO Therapeutics, will take part in a fireside chat on Tuesday, November 17, 2026 at 9:20 a.m. GMT (4:20 a.m. EST, 8:20 p.m. AEDT).

The session will be webcast live, and accessible through Telix’s Investor Relations website.

For more information including how to register, please visit: View Source

(Press release, Telix Pharmaceuticals, NOV 11, 2026, View Source [SID1234674620])